ADC Therapeutics stock price, funding rounds, valuation and financials

ADC Therapeutics has raised $526 m in total funding. ADC Therapeutics annual revenue was $1.14 m in FY 2018

$1.1 M

ADC Therapeutics Revenue FY, 2018
ADC Therapeutics Revenue growth (FY, 2017 - FY, 2018), %(37%)
ADC Therapeutics Net income (FY, 2018)-123.1 M
ADC Therapeutics EBIT (FY, 2018)125.9 M
ADC Therapeutics Cash, 31-Dec-2018138.8 M

ADC Therapeutics Funding

Summary Metrics

Founding Date

2010

ADC Therapeutics total Funding

$526 m

ADC Therapeutics latest funding size

$25 m

Time since last funding

3 months ago

ADC Therapeutics investors

ADC Therapeutics's latest funding round in July 2019 was reported to be $25 m. In total, ADC Therapeutics has raised $526 m

ADC Therapeutics Capital Raised

Embed Graph

ADC Therapeutics Income Statement

Annual

USDFY, 2017FY, 2018

Revenue

1.8m1.1m

Revenue growth, %

(37%)

R&D expense

85.5m118.3m

General and administrative expense

7.9m8.8m

Operating expense total

93.5m127.1m

EBIT

91.7m125.9m

EBIT margin, %

5084%11047%

Pre tax profit

(89.8m)(122.9m)

Income tax expense

48.0k224.0k

Net Income

(89.9m)(123.1m)

ADC Therapeutics Balance Sheet

Annual

USDFY, 2017FY, 2018

Cash

262.8m138.8m

Accounts Receivable

1.1m192.0k

Current Assets

265.2m142.1m

PP&E

1.1m1.5m

Total Assets

271.9m150.6m

Accounts Payable

7.6m6.8m

Current Liabilities

20.5m22.4m

Non-Current Liabilities

2.2m2.0m

Total Liabilities

22.8m24.3m

Common Stock

397.0k401.0k

Additional Paid-in Capital

452.3m452.3m

Retained Earnings

(209.0m)(332.1m)

Total Equity

249.2m126.2m

Financial Leverage

1.1 x1.2 x

ADC Therapeutics Cash Flow

Annual

USDFY, 2017FY, 2018

Net Income

(89.9m)(123.1m)

Depreciation and Amortization

341.0k740.0k

Accounts Receivable

4.8m895.0k

Accounts Payable

5.5m(858.0k)

Cash From Operating Activities

(74.9m)(121.4m)

Purchases of PP&E

(656.0k)(944.0k)

Cash From Investing Activities

(3.2m)(2.5m)

Cash From Financing Activities

197.2m(24.0k)

Net Change in Cash

119.0m(123.9m)

ADC Therapeutics Ratios

USDY, 2018

Financial Leverage

1.2 x

ADC Therapeutics Operating Metrics

Sep, 2019

Clinical Phase Products (Hematology)

3

Clinical Phase Products (Solid Tumor)

2

Preclinical Phase Products (Solid Tumor)

2